Genzyme is to open a research facility in Cambridge's biotechnology cluster.
The US biotechnology giant will open the facility early this year.
It will initially focus on antibody research and possible treatments for cancer, renal and immune-mediated diseases.
References: Financial
Thank you for reading EG
Want to read more? Enjoy a story a week for FREE for one month.
